Editorial: Women in radionuclide therapy: 2023.
作者信息
Lopci Egesta, Matteucci Federica
机构信息
Nuclear Medicine Unit, IRCCS-Humanitas Research Hospital, Rozzano, Italy.
Nuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
出版信息
Front Nucl Med. 2024 May 9;4:1411878. doi: 10.3389/fnume.2024.1411878. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Women in radionuclide therapy: 2023.社论：2023年放射性核素治疗领域的女性
Front Nucl Med. 2024 May 9;4:1411878. doi: 10.3389/fnume.2024.1411878. eCollection 2024.
2
Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer.拓展新型治疗诊断用177Lu-奥曲肽肽受体放射性核素治疗的适应症：默克尔细胞癌中肽受体放射性核素治疗的概念验证
Case Rep Oncol. 2019 Jan 21;12(1):98-103. doi: 10.1159/000496335. eCollection 2019 Jan-Apr.
3
PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.正电子发射断层扫描 SUV 与肽受体放射性核素治疗脑膜瘤摄取相关。
Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1284-8. doi: 10.1007/s00259-012-2124-x. Epub 2012 Apr 20.
4
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements.肽受体放射性核素治疗（PRRT）：创新与改进
Cancers (Basel). 2023 May 30;15(11):2975. doi: 10.3390/cancers15112975.
5
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.十二年肽受体放射性核素治疗随访。
J Nucl Med. 2019 Apr;60(4):524-529. doi: 10.2967/jnumed.118.215376. Epub 2018 Aug 16.
6
Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.最新进展：肽受体闪烁显像及放射性核素治疗的改进策略
Cancer Biother Radiopharm. 2008 Apr;23(2):137-57. doi: 10.1089/cbr.2007.0435.
7
Peptide Receptor Radionuclide Therapy in Thyroid Cancer.甲状腺癌的肽受体放射性核素治疗。
Front Endocrinol (Lausanne). 2022 May 30;13:896287. doi: 10.3389/fendo.2022.896287. eCollection 2022.
8
Clinical efficacy of Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A "not-so-promising" result compared to GEP-NETs.镥-奥曲肽肽受体放射性核素治疗在甲状腺球蛋白升高但碘扫描阴性患者中的临床疗效：与胃肠胰神经内分泌肿瘤相比“不太乐观”的结果
World J Nucl Med. 2020 Jul 1;19(3):205-210. doi: 10.4103/wjnm.WJNM_21_19. eCollection 2020 Jul-Sep.
9
Peptide receptor radionuclide therapy: an overview.肽受体放射性核素治疗：概述
Cancer Biother Radiopharm. 2015 Mar;30(2):47-71. doi: 10.1089/cbr.2014.1741. Epub 2015 Feb 24.
10
Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort.在美国神经内分泌肿瘤队列中，异常的预处理肝功能检查与肽受体放射性核素治疗的停药相关。
Oncologist. 2020 Jul;25(7):572-578. doi: 10.1634/theoncologist.2019-0743. Epub 2020 Mar 6.
本文引用的文献
1
Editorial: Women in radiation oncology: 2021.社论：放射肿瘤学领域的女性：2021年。
Front Oncol. 2023 Mar 17;13:1162683. doi: 10.3389/fonc.2023.1162683. eCollection 2023.
2
Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.精准肿瘤学方向上的当前及未来放射性核素疗法：一篇叙述性综述。
Eur J Radiol Open. 2023 Jan 31;10:100477. doi: 10.1016/j.ejro.2023.100477. eCollection 2023.
3
Radiotheranostics in oncology: current challenges and emerging opportunities.肿瘤放射治疗学：当前的挑战与新兴机遇。
Nat Rev Clin Oncol. 2022 Aug;19(8):534-550. doi: 10.1038/s41571-022-00652-y. Epub 2022 Jun 20.
4
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.十二年肽受体放射性核素治疗随访。
J Nucl Med. 2019 Apr;60(4):524-529. doi: 10.2967/jnumed.118.215376. Epub 2018 Aug 16.
Zotero 插件